Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral
T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature …

Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and
clinically heterogeneous diseases that cannot be further classified into any other of the …

Purpose Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to conventional
therapy. To evaluate the efficacy of a dose-dense approach consolidated by up-front high …

To complement the existing treatment guidelines for all tumour types, ESMO organizes
consensus conferences to focus on specific issues in each type of tumour. In this setting, a …

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly
population that has a poor prognosis when treated with cyclophosphamide, doxorubicin …

Background T‐cell lymphomas make up approximately 10%‐15% of lymphoid
malignancies. The frequency of these lymphomas varies geographically, with the highest …

Background This multicentre, single-arm, open-label phase 2 trial investigated the efficacy
and safety of lenalidomide monotherapy in patients with relapsed/refractory peripheral T-cell …

BACKGROUND Patients with T‐cell lymphomas face a poorer prognosis compared with
patients with B‐cell lymphomas. New therapeutic approaches need to be developed to …

Romidepsin (histone deacetylase inhibitor), lenalidomide (immunomodulatory agent), and
carfilzomib (proteasome inhibitor), have efficacy and lack cumulative toxicity in …

Gamma‐delta T‐cell lymphomas are aggressive and rare diseases originating from gamma‐
delta lymphocytes. These cells, which naturally play a role in the innate, non‐specific …